Asterias Biotherapeutics (AST) shares are rallying in trading today after the company announced positive preliminary data from its Phase 1/2a study, SCiSTAR, assessing its AST-OPC1 (oligodendrocyte progenitor) cells for the treatment of complete cervical spinal cord injury. The data were presented at the 55th Annual Scientific Meeting of the International Spinal Cord Society in Vienna, Austria. All five patients treated with 10M cells showed improved upper extremity scores compared to baseline. At Day 90 of follow-up, four of four patients improved one motor level on at least one side while two of four improved two motor levels on at least one side. One patient improved two levels on both sides. Existing research suggests patients with at least a two-level improvement may regain the ability to perform daily activities such as feeding, dressing and bathing.